# RETAIN-3 (NCT07908979)

> Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: enfortumab vedotin plus pembrolizumab; pembrolizumab
- Indication: muscle-invasive bladder urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07908979
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Fox Chase Cancer Center
- Conditions: Bladder Cancer; Urothelial Carcinoma; Muscle-Invasive Bladder Carcinoma; Muscle-invasive Bladder Urothelial Carcinoma
- Interventions: Enfortumab vedotin; Pembrolizumab; Cisplatin; Gemcitabine; Fluorouracil; Mitomycin c; Radical cystectomy; Radiation therapy
- Enrollment: 70
- Primary outcome: 2-Year Metastasis-Free Survival (MFS)

## Indexed commentary on RETAIN-3 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=retain-3-nct07908979
